Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection : = Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

This is a phase 2b prospective, randomized, single-blind, controlled trial of two weekly subcutaneous injections of lambda interferon alfa-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.

Year of Publication: 2020
Published: Bethesda (Maryland), ClinicalTrials.gov, June 2, 2020
Language: English
Full text access: Full text access (free access)
Links: Full Text (clinicaltrials.gov)
Keywords: Clinical Study Status: Recruiting
Clinical Study
Clinical Trial, Phase II
Forschungsbericht
Infection > MeSH
Klinische Studie
Sars-CoV2
Study Publications:
Notes: Source: ClinicalTrials.gov (no modifications made)
ClinicalTrials.gov processed this data on June 05, 2020
Last update posted on ClinicalTrials.gov: June 2, 2020
Last updated: 2020-06-08
NCT ID:
    NCT04344600

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03026nam a22005172 4500
001 CTG003358631
003 DE-627
005 20200609024418.0
007 cr uuu---uuuuu
008 200609s2020 xx |||||ot 00| ||eng c
028 5 2 |a CTg_2020-06-08.pp 
035 |a (DE-627)CTG003358631 
035 |a (DE-599)NCTNCT04344600 
035 |a (NCT)IRB00248163 
035 |a (NCT)NCT04344600 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
084 |a PHARMAZIE  |q DE-84  |2 fid 
084 |a pha  |2 ssgn 
245 1 0 |a Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection  |b  = Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection 
246 3 1 |a Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection 
264 1 |a Bethesda (Maryland)  |b ClinicalTrials.gov  |c June 2, 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Source: ClinicalTrials.gov (no modifications made) 
500 |a ClinicalTrials.gov processed this data on June 05, 2020 
500 |a Last update posted on ClinicalTrials.gov: June 2, 2020 
500 |a Last updated: 2020-06-08 
520 |a This is a phase 2b prospective, randomized, single-blind, controlled trial of two weekly subcutaneous injections of lambda interferon alfa-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks. 
650 4 |a Clinical Study Status: Recruiting 
650 4 |a Sars-CoV2 
650 4 |a Clinical Study 
650 4 |a Klinische Studie 
650 4 |a Clinical Trial, Phase II 
650 4 |a Infection  |x MeSH 
655 7 |a Forschungsbericht  |2 gnd-content 
710 2 |a Johns Hopkins University  |e Herausgebendes Organ  |4 isb 
787 0 8 |a Hemann EA, Gale M Jr, Savan R  |t Interferon Lambda Genetics and Biology in Regulation of Viral Control  |w (NLM)29270173 
787 0 8 |a Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, Schwemmle M, Günther S, Drosten C, Michiels T, Staeheli P  |t Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections  |w (NLM)20335250 
787 0 8 |a Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK, Fish EN  |t Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study  |w (NLM)14693875 
856 4 0 |u https://clinicaltrials.gov/show/NCT04344600  |z Kostenfrei  |3 Volltext 
912 |a GBV_CTG 
936 u w |j 2020  |b 2  |c 06 
951 |a BO 
952 |j 2020  |b 2  |c 06